Membranous expression of target protein is required for ADC response in urothelial cancer.
European urology
View this publicationMember
PD Dr. med. Niklas Klümper, an advanced clinician-scientist in the ACCENT program at the University Hospital Bonn, focuses on uro-oncology and aims to improve treatment response predictions for targeted therapies, leading to more personalized approaches for uro-oncological diseases. His team has pioneered the prediction of immune checkpoint blockade responses through the analysis of longitudinal inflammatory markers, contributing to the field of immuno-oncology. They are also investigating the mechanisms of resistance to antibody-drug conjugates in patients with metastatic urothelial carcinoma, an emerging area of oncological therapies, and aim to improve precision oncology by tailoring treatment to the molecular profile of patients.
European urology
View this publicationJournal of cellular and molecular medicine
View this publicationCancer medicine
View this publication